Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 4/2011

01.04.2011 | Original Paper

Osteosarcoma: improvement in survival limited to high-grade patients only

verfasst von: Muhammad Umar Jawad, Michael C. Cheung, Jennifer Clarke, Leonidas G. Koniaris, Sean P. Scully

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

We sought to identify the significant prognostic parameters of patients with osteosarcoma over the past three decades using a population-based registry.

Methods

A total of 3765 patients with osteosarcoma were identified in the SEER database. Information regarding patient demographics, clinical and treatment characteristics, cause of death and survival were extracted. Kaplan–Meier, Log-Rank, and Cox regression were used for analysis.

Results

On multivariate analysis only age group ‘<25 years’, ‘local’ stage and ‘low’ grade, ‘appendicular skeleton’ and employment of ‘surgical resection’ showed a disease-specific survival benefit with a P value < 0.001. The long-term survival improved in the interval from 1973 to 1985 from approximately 55 to 65% but subsequent improvement has been limited only to patients with high-grade disease.

Conclusion

When comparing survival rates by decade of diagnosis, it appears that improvement in survival since 1985 is limited to patients with high-grade disease only.

Level of evidence

The level of evidence for this article is 2.
Literatur
Zurück zum Zitat Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342–352PubMedCrossRef Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342–352PubMedCrossRef
Zurück zum Zitat Bacci G, Picci P, Ferrari S, Orlandi M, Ruggieri P, Casadei R, Ferraro A, Biagini R, Battistini A (1993) Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 71:1224–1230PubMedCrossRef Bacci G, Picci P, Ferrari S, Orlandi M, Ruggieri P, Casadei R, Ferraro A, Biagini R, Battistini A (1993) Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 71:1224–1230PubMedCrossRef
Zurück zum Zitat Bacci G, Ferrari S, Sangiorgi L, Picci P, Casadei R, Orlandi M, Iantorno D, Battistini A, Zanone A (1994) Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 6:204–210PubMed Bacci G, Ferrari S, Sangiorgi L, Picci P, Casadei R, Orlandi M, Iantorno D, Battistini A, Zanone A (1994) Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 6:204–210PubMed
Zurück zum Zitat Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161PubMedCrossRef Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161PubMedCrossRef
Zurück zum Zitat Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P (2007) Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 96:118–123PubMedCrossRef Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P (2007) Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 96:118–123PubMedCrossRef
Zurück zum Zitat Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL (2002) Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40:IV-19-25 Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL (2002) Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40:IV-19-25
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790PubMedCrossRef Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790PubMedCrossRef
Zurück zum Zitat Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J et al (1996) Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848–858PubMed Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J et al (1996) Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848–858PubMed
Zurück zum Zitat Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, Rouesse J, Spooner D, Craft AW, Somers R et al (1992) A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10:1579–1591PubMed Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, Rouesse J, Spooner D, Craft AW, Somers R et al (1992) A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10:1579–1591PubMed
Zurück zum Zitat Carsi B, Rock MG (2002) Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 53–61 Carsi B, Rock MG (2002) Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 53–61
Zurück zum Zitat Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, Livingstone AS, Koniaris LG (2008) Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg 12:731–738PubMedCrossRef Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, Livingstone AS, Koniaris LG (2008) Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg 12:731–738PubMedCrossRef
Zurück zum Zitat Clark JC, Dass CR, Choong PF (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134:281–297PubMedCrossRef Clark JC, Dass CR, Choong PF (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134:281–297PubMedCrossRef
Zurück zum Zitat Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL (2002) Use of SEER-Medicare data for measuring cancer surgery. Med Care 40:IV-43-48 Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL (2002) Use of SEER-Medicare data for measuring cancer surgery. Med Care 40:IV-43-48
Zurück zum Zitat Cortes EP et al (1972) Doxorubicin in disseminated Osteosarcoma. JAMA 221:1132–1138CrossRef Cortes EP et al (1972) Doxorubicin in disseminated Osteosarcoma. JAMA 221:1132–1138CrossRef
Zurück zum Zitat Damron TA, Ward WG, Stewart A (2007) Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 459:40–47PubMedCrossRef Damron TA, Ward WG, Stewart A (2007) Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 459:40–47PubMedCrossRef
Zurück zum Zitat Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431PubMed Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431PubMed
Zurück zum Zitat Dupuytren G (1805) Tumors of bone. Bull Ecole Med de Paris 13–24 Dupuytren G (1805) Tumors of bone. Bull Ecole Med de Paris 13–24
Zurück zum Zitat Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL (2002) Identifying cancer relapse using SEER-Medicare data. Med Care 40:IV-75–81 Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL (2002) Identifying cancer relapse using SEER-Medicare data. Med Care 40:IV-75–81
Zurück zum Zitat French Bone Tumor Study Group (1988) Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 61:1304–1311 French Bone Tumor Study Group (1988) Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 61:1304–1311
Zurück zum Zitat Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552PubMedCrossRef Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552PubMedCrossRef
Zurück zum Zitat Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, Watts H, Link M, Jaffe N, Frei E III et al (1987) Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children’s Hospital—study III. J Clin Oncol 5:1178–1184PubMed Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, Watts H, Link M, Jaffe N, Frei E III et al (1987) Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children’s Hospital—study III. J Clin Oncol 5:1178–1184PubMed
Zurück zum Zitat Gross SW (1879) Sarcoma of the long bones. Am J Med Sci 2–57 Gross SW (1879) Sarcoma of the long bones. Am J Med Sci 2–57
Zurück zum Zitat Gutierrez JC, Fischer AC, Sola JE, Perez EA, Koniaris LG (2007a) Markedly improving survival of neuroblastoma: a 30-year analysis of 1, 646 patients. Pediatr Surg Int 23:637–646PubMedCrossRef Gutierrez JC, Fischer AC, Sola JE, Perez EA, Koniaris LG (2007a) Markedly improving survival of neuroblastoma: a 30-year analysis of 1, 646 patients. Pediatr Surg Int 23:637–646PubMedCrossRef
Zurück zum Zitat Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG (2007b) Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 141:105–114PubMedCrossRef Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG (2007b) Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 141:105–114PubMedCrossRef
Zurück zum Zitat Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12:20–37PubMedCrossRef Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12:20–37PubMedCrossRef
Zurück zum Zitat Hendershot E, Pappo A, Malkin D, Sung L (2006) Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. J Pediatr Oncol Nurs 23:176–181PubMedCrossRef Hendershot E, Pappo A, Malkin D, Sung L (2006) Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. J Pediatr Oncol Nurs 23:176–181PubMedCrossRef
Zurück zum Zitat Hwang JE, Cho SH, Kim OK, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Lee JJ, Kim HJ, Chung IJ (2008) Newly developed multiple myeloma in a patient with primary T-cell lymphoma of bone. J Korean Med Sci 23:544–547PubMedCrossRef Hwang JE, Cho SH, Kim OK, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Lee JJ, Kim HJ, Chung IJ (2008) Newly developed multiple myeloma in a patient with primary T-cell lymphoma of bone. J Korean Med Sci 23:544–547PubMedCrossRef
Zurück zum Zitat Institute NC (2008) Surveillance, epidemiology and end results (SEER) Program Institute NC (2008) Surveillance, epidemiology and end results (SEER) Program
Zurück zum Zitat Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim BS, Das L, Frauenberger G, Djerassi I, Cassady JR (1973) Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31:1367–1373PubMedCrossRef Jaffe N, Paed D, Farber S, Traggis D, Geiser C, Kim BS, Das L, Frauenberger G, Djerassi I, Cassady JR (1973) Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31:1367–1373PubMedCrossRef
Zurück zum Zitat Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP (2009a) Ewing’s sarcoma demonstrates racial disparities in incidence and gender related difference in outcome: an analysis of 1631 cases from the SEER database (1973–2005). Cancer 115(15):3526–3536 Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP (2009a) Ewing’s sarcoma demonstrates racial disparities in incidence and gender related difference in outcome: an analysis of 1631 cases from the SEER database (1973–2005). Cancer 115(15):3526–3536
Zurück zum Zitat Jawad MU, Extein J, Min ES, Scully SP (2009b) Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res 467(11):2939–2948 Jawad MU, Extein J, Min ES, Scully SP (2009b) Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res 467(11):2939–2948
Zurück zum Zitat Jeon DG, Lee SY, Cho WH, Song WS, Park JH (2006) Primary osteosarcoma in patients older than 40 years of age. J Korean Med Sci 21:715–718PubMedCrossRef Jeon DG, Lee SY, Cho WH, Song WS, Park JH (2006) Primary osteosarcoma in patients older than 40 years of age. J Korean Med Sci 21:715–718PubMedCrossRef
Zurück zum Zitat Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG (2008) Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol 15:906–914PubMedCrossRef Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG (2008) Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol 15:906–914PubMedCrossRef
Zurück zum Zitat Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC (2004) Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 286–291 Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC (2004) Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 286–291
Zurück zum Zitat Merrill RM, Dearden KA (2004) How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control 15:1027–1034PubMedCrossRef Merrill RM, Dearden KA (2004) How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control 15:1027–1034PubMedCrossRef
Zurück zum Zitat Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5–15PubMed Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5–15PubMed
Zurück zum Zitat Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol 26:633–638PubMedCrossRef Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol 26:633–638PubMedCrossRef
Zurück zum Zitat Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543PubMedCrossRef Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543PubMedCrossRef
Zurück zum Zitat Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202:623–629PubMedCrossRef Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG (2006) Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 202:623–629PubMedCrossRef
Zurück zum Zitat Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS, Franceschi D, Koniaris LG (2007) Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 11:114–125PubMedCrossRef Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS, Franceschi D, Koniaris LG (2007) Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg 11:114–125PubMedCrossRef
Zurück zum Zitat Petrelli NJ (2007) SEER data: it can be thought provoking, but where do we go from here? Ann Surg Oncol 14:2173–2174PubMedCrossRef Petrelli NJ (2007) SEER data: it can be thought provoking, but where do we go from here? Ann Surg Oncol 14:2173–2174PubMedCrossRef
Zurück zum Zitat Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB (2002) Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV-62–68 Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB (2002) Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV-62–68
Zurück zum Zitat Prindull G (1979) Multidrug chemotherapy of osteogenic sarcoma (author’s transl). Blut 39:293–300PubMedCrossRef Prindull G (1979) Multidrug chemotherapy of osteogenic sarcoma (author’s transl). Blut 39:293–300PubMedCrossRef
Zurück zum Zitat Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMed Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMed
Zurück zum Zitat Saeter G, Elomaa I, Wahlqvist Y, Alvegard TA, Wiebe T, Monge O, Forrestier E, Solheim OP (1997) Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 273:156–160PubMed Saeter G, Elomaa I, Wahlqvist Y, Alvegard TA, Wiebe T, Monge O, Forrestier E, Solheim OP (1997) Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 273:156–160PubMed
Zurück zum Zitat Sami SH, Rafati AH, Hodjat P (2008) Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor. Saudi Med J 29:1124–1129PubMed Sami SH, Rafati AH, Hodjat P (2008) Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor. Saudi Med J 29:1124–1129PubMed
Zurück zum Zitat Schrag D, Bach PB, Dahlman C, Warren JL (2002) Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care 40:IV-96–103 Schrag D, Bach PB, Dahlman C, Warren JL (2002) Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care 40:IV-96–103
Zurück zum Zitat Solheim OP, Saeter G, Elomaa I, Alvegard TA (1992) The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 3(Suppl 2):S7–S11 Solheim OP, Saeter G, Elomaa I, Alvegard TA (1992) The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 3(Suppl 2):S7–S11
Zurück zum Zitat Szendroi M, Papai Z, Koos R, Illes T (2000) Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol 73:87–94PubMedCrossRef Szendroi M, Papai Z, Koos R, Illes T (2000) Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol 73:87–94PubMedCrossRef
Zurück zum Zitat Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J (2002) Studying radiation therapy using SEER-Medicare-linked data. Med Care 40:IV-49–54 Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J (2002) Studying radiation therapy using SEER-Medicare-linked data. Med Care 40:IV-49–54
Zurück zum Zitat Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB (2002a) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV-55–61 Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB (2002a) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV-55–61
Zurück zum Zitat Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002b) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3–18 Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002b) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3–18
Zurück zum Zitat Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI (2003) Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14:175–193PubMedCrossRef Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI (2003) Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14:175–193PubMedCrossRef
Zurück zum Zitat Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K (2004) Adjuvant therapy of osteosarcoma—a Phase II trial: Southwest Oncology Group study 9139. Cancer 100:818–825PubMedCrossRef Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K (2004) Adjuvant therapy of osteosarcoma—a Phase II trial: Southwest Oncology Group study 9139. Cancer 100:818–825PubMedCrossRef
Metadaten
Titel
Osteosarcoma: improvement in survival limited to high-grade patients only
verfasst von
Muhammad Umar Jawad
Michael C. Cheung
Jennifer Clarke
Leonidas G. Koniaris
Sean P. Scully
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0923-7

Weitere Artikel der Ausgabe 4/2011

Journal of Cancer Research and Clinical Oncology 4/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.